NeuroBo Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on NeuroBo Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date NeuroBo Pharmaceuticals Inc Strategy Report
- Understand NeuroBo Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Business Description
NeuroBo Pharmaceuticals Inc (NeuroBo) focuses on the development and commercialization of therapies for patients with viral, neuropathic, neurodegenerative diseases, Alzheimer's disease and cardiometabolic disorders, including dyslipidemia, homozygous familial hypercholesterolemia (HoFH), hypertriglyceridemia (SHTG) a serious medical conditions that increases the risk of life-threatening cardiovascular diseases. The company’s pipeline product candidates include ANA001, NB-01, NB-02 and Gemcabene.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
NeuroBo conducts research and development activities that involve the controlled use of potentially hazardous substances, including chemical and biological materials and costs incurred in for the development of its product candidates. It completely relied on third party clinical research organisations(CRO) for its preclinical studies and clinical trials. Failure in the duties and agreements of CROs leads to fines and penalties. The company spent. US$2.8 million for FY2022, which declined 57.6% YoY.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer